Table of Contents Author Guidelines Submit a Manuscript
International Journal of Alzheimer’s Disease
Volume 2010 (2010), Article ID 972685, 6 pages
http://dx.doi.org/10.4061/2010/972685
Review Article

Diagnostic Tests for Alzheimer's Disease: Rationale, Methodology, and Challenges

1Centre of Mental Health, Imperial College London, London W6 8LN, UK
2Nuffield Department of Medicine, University of Oxford, Oxford OX3 7LJ, UK

Received 27 April 2010; Accepted 1 July 2010

Academic Editor: Henrik Zetterberg

Copyright © 2010 S. E. Mason et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Z. S. Khachaturian, “Diagnosis of Alzheimer's disease,” Archives of Neurology, vol. 42, no. 11, pp. 1097–1105, 1985. View at Google Scholar · View at Scopus
  2. S. S. Mirra, A. Heyman, and A. Heyman, “The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease,” Neurology, vol. 41, no. 4, pp. 479–486, 1991. View at Google Scholar · View at Scopus
  3. M. Ball, H. Braak, and H. Braak, “Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease,” Neurobiology of Aging, vol. 18, no. 4, supplement, pp. S1–S2, 1997. View at Publisher · View at Google Scholar · View at Scopus
  4. G. McKhann, D. Drachman, M. Folstein, R. Katzman, D. Price, and E. M. Stadlan , “Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease,” Neurology, vol. 34, no. 7, pp. 939–944, 1984. View at Google Scholar
  5. Z. Nagy, M. M. Esiri, and M. M. Esiri, “Accuracy of clinical operational diagnostic criteria for Alzheimer's disease in relation to different pathological diagnostic protocols,” Dementia and Geriatric Cognitive Disorders, vol. 9, no. 4, pp. 219–226, 1998. View at Publisher · View at Google Scholar · View at Scopus
  6. F. E. Matthews, B. C. M. Stephan, I. G. McKeith, J. Bond, and C. Brayne, “Two-year progression from mild cognitive impairment to dementia: to what extent do different definitions agree?” Journal of the American Geriatrics Society, vol. 56, no. 8, pp. 1424–1433, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. S. J. Tabrizi, D. R. Langbehn, and D. R. Langbehn, “Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data,” The Lancet Neurology, vol. 8, no. 9, pp. 791–801, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. M. H. Tabert, J. J. Manly, and J. J. Manly, “Neuropsychological prediction of conversion to alzheimer disease in patients with mild cognitive impairment,” Archives of General Psychiatry, vol. 63, no. 8, pp. 916–924, 2006. View at Publisher · View at Google Scholar · View at PubMed
  9. B. Dubois, H. H. Feldman, and H. H. Feldman, “Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria,” The Lancet Neurology, vol. 6, no. 8, pp. 734–746, 2007. View at Publisher · View at Google Scholar · View at PubMed
  10. K. Yaffe, G. Sawaya, I. Lieberburg, and D. Grady, “Estrogen therapy in postmenopausal women: effects on cognitive function and dementia,” Journal of the American Medical Association, vol. 279, no. 9, pp. 688–695, 1998. View at Publisher · View at Google Scholar
  11. H. D. Nelson, L. L. Humphrey, P. Nygren, S. M. Teutsch, and J. D. Allan, “Postmenopausal hormone replacement therapy: scientific review,” Journal of the American Medical Association, vol. 288, no. 7, pp. 872–881, 2002. View at Google Scholar
  12. S. A. Shumaker, C. Legault, and C. Legault, “Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial,” Journal of the American Medical Association, vol. 289, no. 20, pp. 2651–2662, 2003. View at Publisher · View at Google Scholar · View at PubMed
  13. L. E. Middleton and K. Yaffe, “Promising strategies for the prevention of dementia,” Archives of Neurology, vol. 66, no. 10, pp. 1210–1215, 2009. View at Publisher · View at Google Scholar · View at PubMed
  14. L. Lannfelt, K. Blennow, and K. Blennow, “Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial,” The Lancet Neurology, vol. 7, no. 9, pp. 779–786, 2008. View at Publisher · View at Google Scholar · View at PubMed
  15. R. Lonergan, K. Kinsella, M. Duggan, S. Jordan, M. Hutchinson, and N. Tubridy, “Discontinuing disease-modifying therapy in progressive multiple sclerosis: can we stop what we have started?” Multiple Sclerosis, vol. 15, no. 12, pp. 1528–1531, 2009. View at Publisher · View at Google Scholar · View at PubMed
  16. D. P. Devanand, X. Liu, and X. Liu, “Combining early markers strongly predicts conversion from mild cognitive impairment to Alzheimer's disease,” Biological Psychiatry, vol. 64, no. 10, pp. 871–879, 2008. View at Publisher · View at Google Scholar · View at PubMed
  17. Cochrane Collaboration, Diagnostic Test Accuracy Handbook, http://srdta.cochrane.org/handbook-dta-reviews.